India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing i.e., 30 percent- 35 percent lower than in the US and Europe, cost-efficient R&D about 87 percent less than in developed markets, and cheap skilled labor. This makes India the top manufacturing hub for pharmaceuticals.
Here are some of the Pharmaceutical companies in which Foreign Institutional Investors have increased their holding by up to 5.12 percent
Strides Pharma Science
Strides Pharma Science is engaged in the business of development and manufacturing of pharmaceutical products. It operates through 2 business segments i.e., pharmaceutical and bio-pharmaceutical.
With a market capitalization of Rs. 8,082 Crores, the shares of Strides Pharma Science Limited were trading at Rs. 870.70 down 0.66 percent from its previous day’s close price of Rs. 876.45.
In Q4FY24, the FII/FPI increased their holding in Strides Pharma Science Limited from 19.45 percent to 24.57 percent by purchasing an additional 5.12 percent stake.
Its revenue from operations grew by 20 percent from Rs. 865 Crores in Q3FY23 to Rs. 1,038 Crores in Q3FY24, accompanied by a loss of Rs. 82 Crores to a profit of Rs. 54 Crores.
Mankind Pharma
Mankind Pharma Limited is one of the leading players in the pharmaceutical industry, it is engaged in developing, manufacturing, and selling a diverse range of markets pharmaceutical formulations across various acute, and chronic therapeutic areas and several consumer healthcare products.
With a market capitalization of Rs. 95,688 Crores, the shares of Mankind Pharma Limited were trading at Rs. 2,382, up 0.61 percent from its previous day’s close price of Rs. 2,368.25.
In Q4FY24, the FII/FPI increased their holding in Mankind Pharma Limited from 6.74 percent to 9.87 percent by purchasing an additional 3.13 percent stake.
Its revenue from operations grew by 21.84 percent from Rs. 1,936 Crores in Q3FY23 to Rs. 2,359 Crores in Q3FY24, accompanied by profits of Rs. 249 Crores to Rs. 487 Crores.
Natco Pharma
Natco Pharma Limited is a vertically integrated, research and development-focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas.
With a market capitalization of Rs. 18,388 Crores, the shares of Natco Pharma Limited were trading at Rs. 1,032, up 0.15 percent from its previous day’s close price of Rs. 1,031.25.
In Q4FY24, the FII/FPI increased their holding in Natco Pharma Limited from 13.72 percent to 16.14 percent by purchasing an additional 2.42 percent stake.
Its revenue from operations grew by 54.26 percent from Rs. 492 Crores in Q3FY23 to Rs. 759 Crores in Q3FY24, accompanied by profits of Rs. 62 Crores to Rs. 213 Crores.
Lupin
Lupin Limited is engaged in the production, development, and marketing of a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally.
With a market capitalization of Rs. 73,512 Crores, the shares of Lupin Pharma Limited were trading at Rs. 1,618.20, up 0.15 percent from its previous day’s close price of Rs. 1,615.85.
In Q4FY24, the FII/FPI increased their holding in Lupin Limited from 16.11 percent to 18.29 percent by purchasing an additional 2.18 percent stake.
Its revenue from operations grew by 20.24 percent from Rs. 4,322 Crores in Q3FY23 to Rs. 5,197 Crores in Q3FY24, accompanied by profits of Rs. 158 Crores to Rs. 619 Crores.
Neuland Laboratories
Neuland Laboratories Limited is engaged in the manufacturing and supplying of bulk drugs catering to both domestic and international markets. It manufactures APIs and end-to-end solutions for the pharmaceutical industry’s needs.
With a market capitalization of Rs. 9,038 Crores, the shares of Neuland Laboratories Limited were trading at Rs. 7,045, up 0.88 percent from its previous day’s close price of Rs. 7,045.
In Q4FY24, the FII/FPI increased their holding in Neuland Laboratories Limited from 22.69 percent to 24.43 percent by purchasing an additional 1.74 percent stake.
Its revenue from operations grew by 46 percent from Rs. 269 Crores in Q3FY23 to Rs. 393 Crores in Q3FY24, accompanied by profits of Rs. 31 Crores to Rs. 81 Crores.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
